Canandaigua National Bank & Trust Company Upped Its Ingersoll (IR) Stake; Last Week Vascular Biogenics Ltd. (VBLT) Analysts

Among 5 analysts covering Vascular Biogenics (NASDAQ:VBLT), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Vascular Biogenics has $27.50 highest and $8 lowest target. $15.25’s average target is 116.31% above currents $7.05 stock price. Vascular Biogenics had 13 analyst reports since August 24, 2015 according to SRatingsIntel. On Monday, September 21 the stock rating was initiated by Chardan Capital Markets with “Buy”. As per Tuesday, October 3, the company rating was maintained by H.C. Wainwright. Chardan Capital Markets maintained Vascular Biogenics Ltd. (NASDAQ:VBLT) rating on Friday, October 23. Chardan Capital Markets has “Buy” rating and $27.50 target. Piper Jaffray initiated the shares of VBLT in report on Monday, November 9 with “Overweight” rating. The stock of Vascular Biogenics Ltd. (NASDAQ:VBLT) has “Buy” rating given on Tuesday, November 7 by H.C. Wainwright. On Tuesday, March 28 the stock rating was maintained by H.C. Wainwright with “Buy”. JMP Securities maintained it with “Market Outperform” rating and $8 target in Wednesday, March 9 report. The rating was maintained by Roth Capital on Monday, September 28 with “Buy”. The rating was initiated by H.C. Wainwright on Tuesday, June 28 with “Buy”. On Monday, September 21 the stock rating was upgraded by JMP Securities to “Mkt Outperform”. See Vascular Biogenics Ltd. (NASDAQ:VBLT) latest ratings:

07/11/2017 Broker: H.C. Wainwright Rating: Buy New Target: $11.0 Maintain
30/10/2017 Broker: Chardan Capital Markets Rating: Buy New Target: $20.0
03/10/2017 Broker: H.C. Wainwright Rating: Buy New Target: $11.0 Maintain
15/08/2017 Broker: H.C. Wainwright Rating: Buy New Target: $11.0000 Maintain

Canandaigua National Bank & Trust Company increased Ingersoll (IR) stake by 104.77% reported in 2017Q3 SEC filing. Canandaigua National Bank & Trust Company acquired 9,000 shares as Ingersoll (IR)’s stock rose 10.19%. The Canandaigua National Bank & Trust Company holds 17,590 shares with $1.57M value, up from 8,590 last quarter. Ingersoll now has $22.43 billion valuation. The stock decreased 0.67% or $0.61 during the last trading session, reaching $89.77. About 1.30M shares traded. Ingersoll-Rand Plc (NYSE:IR) has risen 39.42% since December 24, 2016 and is uptrending. It has outperformed by 22.72% the S&P500.

Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company has market cap of $209.56 million. The companyÂ’s program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. It currently has negative earnings. The Company’s lead product candidate is VB-111, a gene biologic that is in Phase III clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer; and has completed Phase II clinical trials for recurrent platinum-resistant ovarian cancer, as well as for iodine-resistant differentiated thyroid cancer.

The stock increased 2.55% or $0.18 during the last trading session, reaching $7.05. About 103,460 shares traded. Vascular Biogenics Ltd. (NASDAQ:VBLT) has risen 78.91% since December 24, 2016 and is uptrending. It has outperformed by 62.21% the S&P500.